INTRODUCTION
An important element in the development of DNA-active antitumor agents is understanding the requirements for molecular recognition. Minor groove binding drugs, such as distamycin, netropsin and the bisquaternary ammonium heterocycles (bQAHs), bind reversibly to DNA and serve as excellent model systems not only for study of the physical requirements, but also for examination of the thermodynamic and kinetic parameters involved in drug-DNA complex formation. These minor groove binding ligands are crescent-shaped elongated structures consisting of planar units with strategically placed hydrogen bond donors and acceptors. They are known to have a preference for AT sequences and to exert antitumor activity by interfering with DNA metabolism. The molecular basis of the interactions between DNA duplexes and minor groove binding drugs has been probed by various biophysical techniques, including X-ray crystallography [netropsin (1) (2) (3) (4) , distamycin (5) , Hoechst 33258 (6-11)] and NMR spectroscopy [netropsin (12) (13) (14) , distamycin (15) (16) (17) (18) (19) , Hoechst 33258 (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) ]. These studies have identified specific molecular features that affect relative affinity and the AT preference of these ligands. Fig. 1a ) is a member of the family of bQAH DNA binding agents that possess potent antitumor and antiviral activities both in vitro and in vivo (30, 31) and which act as inhibitors of DNA gyrase (32) . These molecules have distinct structural features that set them apart from the oligopeptide antibiotics (e.g. multiple monocationic π-systems) and affect the details of the binding interactions. There have been very few high resolution studies of bQAH-DNA complexes: a single X-ray crystal structure of SN-6999 with an alkylated DNA duplex (33) and three NMR studies (34) (35) (36) . In order to elucidate the molecular basis for the binding of the ligand to DNA and to attempt a rational design of more potent derivatives, it is necessary to generate additional structural, kinetic and thermodynamic information for bQAH-DNA complexes.
SN-6999 (1-methyl-4-[4-[4-(4-(1-methylquinolinium)amino)-benzamido]anilino] pyridinium dibromide;
NMR studies of 1:1 complexes of SN-6999 with two DNA duplexes have been reported previously. The first of the duplexes was a palindrome, d(GCATTAATGC) 2 (ATTAAT duplex), for which the experimental data revealed minor groove binding specifically in the AT-rich central region, with binding kinetics in an intermediate to fast regime (on the NMR chemical shift time scale) and rapid exchange between the symmetrically equivalent binding sites (34, 35) . Detailed interpretation of these data was complicated by the symmetry of the duplex, the fast exchange between the equivalent sites and the potential for sliding of the drug along the minor groove. The second DNA duplex, d(GGTTAATGCGGT)·d(ACCGCATTAACC) (TTAAT duplex), was designed to optimize the binding site and remove the internal symmetry (36) . The AT-rich binding site was reduced to 5 bp to match the excluded site size determined by optical spectroscopy (37) , presumably limiting the potential for sliding. The NMR data for this complex showed that SN-6999 interacts primarily with the AT-rich region, but also with one additional residue in the 3′-direction on each strand (G8 and C23). Interactions with guanosine or cytosine residues adjacent to the AT-rich region had not been observed in previous studies, but were subsequently also seen in the X-ray crystal structure of the complex with an alkylated duplex (33) . In solution studies of both the ATTAAT and the TTAAT complexes the experimental data were consistent with rapid exchange between two binding orientations along the DNA helix axis via a 'flip-flop' mechanism. However, high resolution structural analysis was precluded by the inability to freeze out, or in some other way distinguish, the two sets of signals for detailed analysis of the two binding orientations.
In this report we describe NMR analysis of the SN-6999 complex with the DNA duplex d(GGGAAAAACGG)·d(CCGT-TTTTCCC) (AAAAA duplex; Fig. 1b ), designed with a central core of five AT base pairs to match the excluded site size for SN-6999 binding. The central d(A) 5 ·d(T) 5 sequence was specifically incorporated to take advantage of the known propensity for (dA) n tract sequences to generate duplexes with a narrowed minor groove (38, 39) . Our premise was that this structural feature would lead to a longer lifetime for the bound ligand in the DNA minor groove.
MATERIALS AND METHODS
The methods used for synthesis and purification of SN-6999 and the two oligonucleotides, as well as bis-quaternization of the ligand with 13 C-enriched CH 3 I, have been described elsewhere (34) (35) (36) 40) . The complementary oligonucleotides d(GGGAAAAACGG) and d(CCGTTTTTCCC) were mixed in equimolar amounts (as monitored by 1 H NMR at 75_C), then lyophilized, redissolved in 420 µl buffer (50 mM sodium phosphate, pH 7.0, 100 mM NaCl, 0.003% NaN 3 , 0.2 mM EDTA and 5% 2 H 2 O) and annealed. The final concentration was 1 mM as determined by UV absorption methods, using molar extinction coefficients (ε 260 nm ) of 83 300/M/cm for d(CCGTTTTTCCC) and 145 100/M/cm for d(GGGAAAAAC-GG). For experiments to examine only non-labile protons the solution was repeatedly lyophilized from 99.96% 2 H 2 O, followed by dissolution in 99. NMR experiments were performed using Bruker AMX-500, AMX-600 and AMX2-500 spectrometers. For the free DNA duplex the temperature was 28_C for experiments in 2 H 2 O solution and -3_C for experiments in 1 H 2 O solution. For the complex the temperature was varied from 1 to 37_C. The spectra were acquired as reported previously (36, 42) . Double quantum filtered COSY, triple quantum filtered COSY, double quantum (2Q), triple quantum and TOCSY spectra were recorded for the free AAAAA duplex, but only 2Q for the complex. NOESY spectra from 2 H 2 O solution were recorded with mixing times of 50-200 ms, saturation of the residual water signal during both the preparation and mixing periods, and a Hahn echo prior to acquisition to improve the quality of the baseline. Since the SN-6999 methyl groups were 13 C enriched, one NOESY spectrum (τ m = 200 ms) for the complex was acquired with 13 C decoupling. Decoupling was achieved by a 180_ 13 C pulse midway through the evolution time and 13 C GARP decoupling (43) during acquisition. All NOESY spectra from 1 H 2 O solution were recorded with a mixing time of 200 ms and solvent suppression by replacing the observe pulse with a jump-return composite sequence (44) . In addition to the standard experiments, a ROESY (45,46) spectrum for the complex was acquired at 7_C using a 50 ms 1.7 G continuous wave spin lock for mixing, 32 scans/t 1 value and a t 1max of 29 ms. Also, two 2D 13 C-1 H heteronuclear single quantum coherence (HSQC) NOESY (47,48) spectra were acquired for the complex at 1_C with 80 and 200 ms mixing periods, 64 scans/t 1 value, t 1max of 15 ms and no presaturation of the water signal. The NMR data were processed using a Sun IPX workstation with Felix software (Biosym Inc., San Diego, CA).
The model for the complex was constructed using Insight 2.3 (Biosym Inc., San Diego, CA). The d(GGGAAAAACGG)·d (CCGTTTTTCCC) duplex was built in standard B-DNA geometry. The coordinates for SN-6999 were taken from the X-ray structure of the complex with an alkylated DNA duplex (33) , kindly provided by Prof. Andrew H.-J. Wang (University of Illinois). The ligand was manually docked in the DNA minor groove on the basis of the intermolecular NOEs associated with the preferred orientation. This starting model was refined by two cycles of energy minimization in the AMBER 4.0 force-field (49), using the experimentally determined intermolecular contacts as restraints (rEM). The first cycle consisted of 5000 steps of rEM in the AMBER 4.0 force field using the drug-DNA distance restraints set conservatively to a value of 5 Å, except those from very weak cross-peaks which were assigned to 6 Å, and with the DNA atoms positionally restrained. This structure was then further refined by 5000 steps of rEM with all atoms free to move. In the resulting structure, all 21 intermolecular contacts were largely satisfied, with only two violations >0.1 Å, both <0.13 Å.
RESULTS AND DISCUSSION

H NMR of the free duplex
The strategies for 1 H NMR analysis of small DNA duplexes have been amply reviewed (50) (51) (52) (53) (54) and the specific protocol used in this work has previously been described (40, 42) . All cytosine 5H/6H, thymine 5CH 3 /6H and 1′H-2′H-2′′H-3′H-4′H resonances were identified by scalar connectivites in the COSY, multiple quantum and TOCSY spectra. An exhaustive analysis of these spectra was required due to the high degree of spectral degeneracy associated with the d(A) 5 ·d(T) 5 (Fig. 3) . Studies of the temperature dependence of the NMR spectrum performed at a drug:DNA ratio of 0.87:1 showed that some resonances remain doubled up to 37_C, indicating slow to intermediate exchange on the NMR time scale even at higher temperatures. This observation contrasts sharply with observations made in previous studies of SN-6999 complexed to other DNA duplexes (34, 36) .
Titration of SN-6999 into the DNA solution also causes an increase in the linewidth of DNA and drug resonances. In general, the linewidth effects were found to be extremely sensitive to temperature and small changes in the drug:DNA ratio, particularly for ratios near 1:1. Continued titration of ligand beyond the 1:1 ratio to an estimated limit of 1.09:1 resulted in a sharpening of the DNA resonances, although these clearly remain significantly broader than for the free DNA. This is accompanied by broadening of ligand resonances. These phenomena were fully reversible, i.e. back titration of free DNA duplex to the 'overtitrated' solution resulted in a return of the spectrum to that of the equimolar solution. The results are consistent with all DNA binding sites being filled with one drug molecule per DNA molecule. The inability to introduce an additional equivalent of drug indicates that 2:1 binding modes, such as those observed for the distamycin family of minor groove binding agents (see for example [17] [18] [19] 55, 56) , are not formed for SN-6999.
The sequence-specific resonance assignments of the complex were obtained in a manner similar to our previous studies (34) (35) (36) . To obtain the maximum number of unambiguous assignments, spectra were recorded under a variety of experimental conditions. In general, solutions containing an excess of drug at higher temperatures produced the best spectral properties for assigning the DNA resonances, while equimolar or lower drug ratios at temperatures near 0_C facilitated assignment of the drug resonances and the identification of intermolecular contacts.
The sequence-specific assignments of the imino NH proton, cytosine NH 2 and adenine 2H resonances were obtained from the NOESY spectra with a 1:1 drug:DNA ratio. Resonances were assigned first at 1_C, then transferred to spectra at 28_C. As noted above, several of the imino proton (and A2H) resonances are split into major and minor signals. Since cross-peaks due to chemical exchange were apparent in the NOESY spectra (vide infra), it was important to distinguish these chemical exchange cross-peaks from the standard sequential NOEs. Consequently, a very careful analysis of the intrabase pair and sequential connectivities to all other protons was required for each spectrum.
The non-exchangeable proton resonances of the DNA were assigned primarily from the 2Q and NOESY spectra recorded at 37_C with ∼9% molar excess of drug, conditions giving rise to the best spectral properties for these resonances. A 2Q experiment collected at 37_C with a drug:DNA ratio of ∼0.8:1 was used as a point of departure to assign the aromatic protons of the drug, because these conditions provided the most complete set of connectivities. Assignments were transferred to NOESY spectra acquired at different drug:DNA ratios and/or lower temperature, to confirm certain overlapped or missing cross-peak assignments and assign the intermolecular NOEs. The chemical shift assignments for the complex are provided as supplementary material (tables S2 and S3). The relative intensities of key cross-peaks in a 50 ms NOESY spectrum [e.g. (34, 36) , significantly greater chemical shift differences are observed for Q-2H, Q-3H, BP-2,6H, BP-3,5H and P/BP NH in the AAAAA complex. Thus, whereas the pattern of chemical shift changes in the DNA and drug resonances are similar to those observed for previously studied SN-6999 complexes (34, 36) , the magnitude of the changes for the AAAAA duplex are generally larger. This suggests a stronger binding interaction.
A close examination of the chemical shift changes induced upon drug binding revealed a rather surprising observation. While nearly all of the chemical shift changes followed expected trends, the imino protons in the drug binding site were extremely peculiar, with fluctuations between upfield and downfield shifts relative to the free DNA. It is generally accepted that drugs binding in the minor groove induce downfield shifts for the imino protons of Watson-Crick pairs, while intercalators have the opposite effect (57, 58) . Studies of the ATTAAT and TTAAT complexes with SN-6999 under fast exchange conditions revealed downfield shifts of imino protons in the binding site. In the AAAAA complex the imino protons of T 19 , T 18 and T 17 are shifted to a higher field upon binding, whereas those of G 3 , T 16 , T 15 and G 14 are shifted to a lower field. Except for T 19 , the unusual upfield shifts also correlate with observation of significant chemical shift differences between the resonances for the major and minor species (Fig. 4) . Upfield shifts of imino protons have also been reported in another drug-DNA complex with a minor groove binding agent, the distamycin analog FCE-24517 (59). Interestingly, doubling of proton resonances and corresponding slow exchange between binding sites was also observed in their study.
Direct information about the structure of the complex is provided by the numerous intermolecular proton-proton contacts identified in the NOESY spectra. An example of the quality of the data is provided in Figure 5 , with the intermolecular cross-peaks highlighted by circles. A table of all unambiguously identified intermolecular NOEs is provided as supplementary material (table S4) . Intermolecular contacts involving protons of SN-6999 are observed in the minor groove throughout the central AT-rich tract, indicative of the drug being positioned parallel to the DNA helical axis. The 2D 13 C-1 H HSQC NOESY spectrum greatly facilitated identification of P-CH 3 and Q-CH 3 contacts that orient the drug within the minor groove in a direct manner, clearly indicating that the P ring is near to the 5′-end of the (+) strand for the major binding mode. The observation of intermolecular NOEs and slowed solvent exchange for BQ/BP-NH implies that the amide proton of the drug points towards the floor of the minor groove and is involved in an intermolecular hydrogen bond. The 2 (25, 26) , as well as in the X-ray crystal structure of SN-6999 complexed to an alkylated DNA duplex (33) .
Although a few drug-drug NOEs corresponding to the chemical shifts unique for the minor form were identified, weak signal intensity and spectral overlap severely limited unambiguous assignment of the corresponding drug-DNA NOEs for these resonances. Only three intermolecular NOEs involving drug resonances of the minor species of the complex could be assigned unambiguously: C 9 1′H/P-CH 3 ; T 16 CH 3 /P-CH 3 ; A 5 2H/BQ-2,6H. The NOE between C 9 1′H and P-CH 3 is of particular note because it appears to be stronger than its counterpart for the major orientation. It must represent therefore a relatively close contact, which specifies the orientation of the drug in the DNA minor groove, i.e. the reverse of that determined for the major binding mode.
Stuctural model of SN-6999 complexed to the AAAAA duplex
To obtain a clearer understanding of the interactions between SN-6999 and the AAAAA duplex we calculated a structural model based on the NMR data for the major species. In this model (Fig. 6 ) it is readily apparent that SN-6999 fits snugly into the curved contour of the minor groove of the 11mer duplex and is situated within the AT-rich region with the bulkier Q ring at the 3′-end of the d(A) 5 tract. The curvature of the ligand is achieved by adjustment of the dihedral angles at the amino linkers; both the Q and P rings are twisted relative to the co-planar BQ and BP rings. All features are fully consistent with the estimated overall length of 18.5 for SN-6999 and the observation of 5 bp sites being fully excluded by drug binding (37) . The extension of contacts of the drug to C 9 on one end and to C 20 on the other end of the d(A) 5 tract are seen to arise as a by-product of the helical twist of the DNA.
The X-ray crystal structure of the complex between SN-6999 and the ethylated self-complementary dodecamer duplex d(CGC[e6G]AATTCGCG) 2 has been determined at 2.5 resolution (33) . In that complex SN-6999 binds as expected in the minor groove covering the central AATT sequence, but is offset toward the e6G 4 residue. The drug spans over 5 bp in the minor groove, with the bulkier Q ring near the T 8 -A 17 bp and the P ring near the e6G 4 -C 21 bp. The BQ and BP rings are co-planar, with the Q and P rings twisted by 38_ and -39_ relative to the BQ/BP plane. A single intermolecular hydrogen bond is found, between the amide NH of SN-6999 and T 20 O2. The structural model of the complex of SN-6999 with the AAAAA duplex is fully consistent with each of these features, despite the potential for perturbations associated with the ethylated nucleotide. For example, the observed NOEs and a slowed rate of solvent exchange of the SN-6999 amide provides good evidence in support of the intermolecular hydrogen bond. The one unique feature of the X-ray structure that is not reflected in our model is bending of the duplex, which is attributed by Wang and co-workers to straightening of the minor groove to accommodate SN-6999. This subtle detail of structure can only be analyzed reliably from a high resolution solution structure, not from the currently available model.
Binding dynamics
As noted above, proton resonances in the 1 H NMR spectrum of the complex shift, broaden and split into two signals with changes in temperature. At 1_C the Q-5H, Q-7H, Q-8H, BP-2,6H, BP-3,5H, P-CH 3 , Q/BQ-NH, BQ/BP-NH and P/BP-NH resonances of the drug are clearly split into two signals. A number of DNA resonances also exhibit resonance doubling, including the imino protons of G 3 , T 18 , T 17 , T 16 and T 15 , as well as A 8 2H, located deep in the minor groove, and C 9 6H, A 8 8H, A 6 1′H and C 21 1′H, located at the edge of the floor of the DNA minor groove. The BQ/BP amide proton shows the largest chemical shift difference (0.13 p.p.m.) between the major and minor species and a 7:3 ratio was determined for the two well-resolved signals directly in 1D spectra. The same ratio has been measured for other protons in 1D spectra and from pairs of resolved cross-peaks in 2D spectra.
Direct chemical exchange between the major and minor species could be identified for protons exhibiting sufficiently resolved resonances. Figure 3 illustrates chemical exchange cross-peaks for the three labile SN-6999 protons. The situation in the aromatic region was more complex, due to the overlap of chemical exchange cross-peaks with intra-and intermolecular NOEs (Fig.  5) . However, all but one of the cross-peaks attributed to chemical exchange could be confirmed in the ROESY spectrum. The sole exception was ambiguous due to spectral overlap.
Having shown that the two species correspond to an equilibrium between two modes of binding, estimates of the rate of exchange between binding sites and the activation energy for this process were made from the temperature dependence of the 1 H NMR resonances. The coalescence temperatures were determined from 1D and 2D NMR spectra. A lower limit for the rate of exchange at the coalescence temperature was calculated from the limiting chemical shift differences measured in the slow exchange regime (60) . The most accurate rates were for P/BP-NH and BQ/BP-NH, giving values of k major > 24/s, k minor > 56/s at 14_C and k major > 59/s, k minor > 138/s at 28_C respectively. These values correspond to upper limits on the lifetime of the drug in the major binding mode of 42 ms at 14_C and 17 ms at 28_C, consistently longer than the lifetimes found for SN-6999 binding to ATTAAT and TTAAT duplexes (34, 36) . An estimate of the activation energy (∆G } ) for this exchange process at the coalescence temperature, based on transition state theory (60) , gives values of 60 ± 3 kJ/mol at 14_C (P/BP-NH) and 61 ± 2 kJ/mol at 28_C (BQ/BP-NH). These are very similar to the values of 60 and 62 kJ/mol respectively for the ATTAAT and TTAAT complexes (34, 36) . The close similarity of the various estimates of ∆G } strongly suggests that the exchange process observed in all three complexes corresponds to the same phenomenon.
The equilibrium between the two binding modes is attributed to SN-6999 undergoing flip-flop exchange (15, 34) in the minor groove of the AAAAA duplex. This phenomenon is an inherent property of most non-covalent minor groove binding agents, reflecting the generalized binding preference for the deep and narrow d(AT) minor groove, but at the same time a lack of true sequence specificity. Note the critically important distinction between sequence preference and true specificity, as these terms are often incorrectly used interchangeably: a truly sequence-specific agent would not exhibit flip-flop exchange. Although activation energies reported for non-covalent minor groove binding agents are rather similar, there is a vast range in the observed lifetimes, from the millisecond to the second time scales. The cumulative results from this and the previous studies of SN-6999 complexed with other DNA duplexes are consistent with the general consensus that the energetics of binding of minor groove ligands is sensitive not only to the molecular structure of the agent, but also to the specific characteristics of the DNA minor groove.
CONCLUDING REMARKS
The AAAAA duplex was designed with a central AT-rich sequence bounded by GC (or CG) base pairs to preclude sliding of the ligand in the minor groove, using the guanine amino group (G-2NH 2 ) that protrudes into the minor groove as a steric constraint. The d(A) 5 ·d(T) 5 sequence was specifically chosen because of the reduced width of its minor grove, which we hypothesized would increase the lifetime of the bound ligand. In fact, the upper limit for the lifetime of the drug in the preferred orientation is substantially longer than that observed for ATTAAT and TTAAT duplexes. Furthermore, we observed, for the first time in a SN-6999 complex, a preferred orientation for the drug in the DNA minor groove, in which the pyridinium (P) ring is located at the 5′-end of the d(A 5 ) tract. Although the 7:3 binding preference is small in energetic terms, it is interesting that a preference is observed in such a symmetrical binding site.
Why does the SN-6999 complex with the AAAAA duplex exhibit longer bound drug lifetimes and differential populations of the two drug orientations? The binding preference in the DNA minor groove is the result of a balance between several stabilizing forces, including steric effects and details of the shape complementarity of the two molecules. In the DNA duplex the thymine bases are all along one side of the minor groove and the adenine bases along the other, with a GC base pair at one end of the d(A) 5 ·d(T) 5 tract and a CG base pair at the other. The exocyclic amino group of guanine reduces the space available for the drug, presumably forming a boundary to the binding site. In the major binding mode the amino group is located on the (+)d(A) 5 strand at the P ring end of SN-6999 and on the (+)d(T) 5 strand at the Q ring end and we find that the drug associates more closely with the opposing strand in each case. This observation strongly supports the significant influence of steric factors on drug binding.
The influence of shape complementarity is evident from a comparison of the results for the three SN-6999 complexes. The AAAAA duplex has been designed to maximize stabilization of the complex by van der Waals interactions, incorporating a d(A) 5 tract which is known to lead to a decreased width of the minor groove. This feature is expected to improve the complementarity of non-polar groups of SN-6999 and the DNA sugar atoms along the walls of the minor groove and lead to tighter binding. The success of this design is apparent in the longer drug lifetimes in the bound state of the AAAAA complex versus the ATTAAT and TTAAT complexes. Shape complementarity is likely to be the primary driving force for the observed orientational preference for drug binding, there being a 'better fit' of the ligand in the DNA minor groove in the major orientation versus the minor orientation. The hydrogen bond between the drug amide proton and the DNA duplex noted above in the X-ray crystal structure of the SN-6999 complex could also play a role in the observed orientational preference if it is better accommodated in one orientation relative to the other. The determination of a high resolution solution structure of this complex should provide detailed insights into the molecular basis for binding of SN-6999 to duplex DNA, the reasons for the differences in the binding energies and kinetics of the three complexes that have been studied, and a critical foundation for the ultimate goal of designing new DNA binding agents with improved therapeutic activities.
SUPPLEMENTARY MATERIAL
Tables with chemical shift assignments for the free DNA (table S1), the SN-6999 complex at 28_C (table S2) and the labile protons in the complex at 1_C (table S3) , a table (S4) listing the intermolecular NOEs, and the coordinates and an image of the structural model. This information is available at http://www.scripps.edu/∼chazin/ supp-mat/NAR .
